Objective:

To ascertain the most effective therapeutic strategy concerning overall survival (OS) at the initial recurrence of glioblastoma.

Approach:

Key Findings:

• Tumor recurrence occurs in approximately 75% of individuals within a year of diagnosis.
• Median overall survival for recurrent GBM is under 2 years.
• Limited information exists on the comparison of various strategies for managing recurrence.

Interpretation:

The study aims to provide insights into the effectiveness of different therapeutic strategies for recurrent glioblastoma, focusing on overall survival outcomes.

Limitations:

• The study is retrospective and conducted at two institutions, which may limit generalizability.
• Exclusion of patients with IDH-mutant GBM and secondary GBM may affect the applicability of findings.

Conclusion:

The FROST study seeks to clarify the impact of multimodal versus singular therapeutic methods on survival outcomes in recurrent glioblastoma patients.

Source

Based on findings from:

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma

Jean-Baptiste Barbe-Richaud, Hélène Cebula, Julien Todeschi, Marie des Neiges Santin, Seyyid Baloglu, Roland Schott, Mathieu Cotton, Aurélien Blouet, Maxime Bobin, Georges Noël, Laura Somme. Journal Of Neuro-Oncology, 2026.

https://link.springer.com/article/10.1007/s11060-026-05635-y

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.